Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | CD38 | P28907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16854657 | 0.89 | SLC6A4 (0.37) | SLC6A4SLC6A2NOS3NOS1NOS2 | |
| SCHEMBL1088444 | 0.89 | SLC6A2 (0.43) | SLC6A4SLC6A2NOS3NOS1NOS2 | |
| SCHEMBL20521564 | 0.89 | SLC6A4 (0.40) | SLC6A4SLC6A2NOS3NOS1NOS2 | |
| Bromide SCHEMBL1306727 | 0.89 | SLC6A4 (0.40) | SLC6A4SLC6A2NOS3NOS1NOS2 | |
| SCHEMBL12120419 | 0.89 | SLC6A4 (0.40) | SLC6A4SLC6A2NOS3NOS1NOS2 | |
| SCHEMBL24680877 | 0.89 | SLC6A4 (0.40) | SLC6A4SLC6A2NOS3NOS1NOS2 | |
| SCHEMBL3436793 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL4349290 | 0.83 | PIK3CD (0.37) | CYP2D6HRH1KCNH2PIK3CDTACR1 | |
| SCHEMBL3436790 | 0.83 | PIK3CD (0.37) | CYP2D6HRH1KCNH2PIK3CDTACR1 | |
| SCHEMBL23634795 | 0.82 | NOS3 (0.33) | SLC6A4SLC6A2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331035-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-06-17 | — | — | US | disclosed |
| EP-4050006-B1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2025-01-01 | — | — | EP | disclosed |
| CN-112313207-B | Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof | 北京赛特明强医药科技有限公司 | 2023-02-14 | — | — | CN | disclosed |
| US-20230023140-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-01-26 | — | — | US | disclosed |
| EP-4050006-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2022-08-31 | — | — | EP | disclosed |
| CN-114945562-A | Bicyclic compounds and uses thereof | 爱思开生物制药株式会社 | 2022-08-26 | — | — | CN | disclosed |
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3848367-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-07-14 | — | — | EP | disclosed |
| WO-2021080359-A1 | BICYCLIC COMPOUND AND USE THEREOF | 에스케이바이오팜 주식회사 | 2021-04-29 | — | — | WO | disclosed |
| CN-112313207-A | Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof | 北京赛特明强医药科技有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080207611-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| EP-1812444-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| EP-1812445-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| EP-1790641-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006046035-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CRBN, CSNK2A1, CSNK2A2 | SLC6A4 4088/4885SLC6A2 4023/4885NOS3 3539/4885 |
| US-20230023140-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | SLC6A4 4811/4885SLC6A2 4810/4885NOS3 337/4885 |
| US-12331035-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | SLC6A4 4811/4885SLC6A2 4810/4885NOS3 337/4885 |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | HSD11B1, HSD11B2, HSD3B1 | SLC6A4 440/4885SLC6A2 861/4885NOS3 327/4885 |
| US-20080207611-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | SLC6A4 2558/4885SLC6A2 3408/4885NOS3 634/4885 |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | PI4KA, DMPK, PDPK1 | SLC6A4 4267/4885SLC6A2 4214/4885NOS3 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.